Analyzing Blood Metabolite Characteristics in Recently Born Preterm Infants with Bronchopulmonary Dysplasia Using LC–MS/MS
After collecting dried blood spots from preterm infants with gestational age (GA) of less than 32 weeks within 24 hours after birth, researchers used liquid chromatography-tandem mass spectrometry (LC–MS/MS) to perform targeted measurements of metabolites to identify differential metabolites in preterm infants with bronchopulmonary dysplasia and uncovering circulating biomarkers for the early prediction of this chronic lung disease.
Researchers from the Department of Pediatrics at Peking University Shenzhen Hospital (Shenzhen, China) analyzed the characteristics of blood metabolites within 24 hours after birth in preterm infants with bronchopulmonary dysplasia (BPD) and to identify biomarkers for predicting the occurrence of BPD. Metabolites were measured using liquid chromatography-tandem mass spectrometry (LC–MS/MS). A paper based on this research was published in Frontiers in Pediatrics (1).
A common chronic lung disease among premature infants, the survival rate of extremely preterm infants with BPD has significantly improved with advances in medical care, rising from 56.4% in 2010 to 67.1% in 2019 (2). The incidence of BPD, however, has not noticeably decreased and remains high (3,4). BPD not only prolongs hospital stays and increases medical costs for preterm infants, but also results in adverse short- and long-term respiratory and neurological outcomes and can even lead to death (5–9).
The researchers collected venous blood DBS and used LC–MS/MS to analyze 86 metabolites. The results reveal significant metabolic differences in amino acids and carnitines between infants with BPD and those without. The researchers identified four differential metabolites in those with gestational age (GA) of less than 28 weeks: histidine, ornithine/citrulline, propionylcarnitine/carnitine, and valerylcarnitine/carnitine, which suggests that histidine may have potential value in the early prediction of BPD in preterm infants with GA of less than 28 weeks (1).
The authors state that their study has its limitations. They conducted targeted metabolomics analysis using samples collected within the first 24 hours after birth. The limited variety of detected metabolites prevented the identification of significant metabolic pathways, potentially overlooking important metabolites. Furthermore, the subgroup analyses were restricted to gestational age and birth weight due to the small sample size, without precise adjustment for other influencing factors. Therefore, based on the preliminary results of this study, the team reported that they have collaborated with the Shenzhen Neonatal Data Network to establish a prospective, multicenter, large-scale, long-term follow-up cohort of infants born preterm at less than 32 weeks of gestation (1).
Premature baby kept under neonatal care. © RFBSIP - stock.adobe.com
References
1. Guo, Y.; Chen, J.; Zhang, Z.; Liu, C.; Li, J.; Liu, Y. Analysis of Blood Metabolite Characteristics at Birth in Preterm Infants with Bronchopulmonary Dysplasia: An Observational Cohort Study. Front. Pediatr. 2024, 12, 1474381. DOI: 10.3389/fped.2024.1474381
2. Zhu, Z.; Yuan, L.; Wang, J.; Li, Q.; Yang, C.; Gao, X.; Chen, S.; Han, S.; Liu, J.; Wu, H.; Yue, S.; Shi, J.; Cheng, R.; Cheng, X.; Han, T.; Jiang, H.; Bao, L.; Chen, C. Mortality and Morbidity of Infants Born Extremely Preterm at Tertiary Medical Centers in China From 2010 to 2019. JAMA Netw. Open. 2021, 4 (5), e219382. DOI: 10.1001/jamanetworkopen.2021.9382
3. Cao, Y.; Jiang, S.; Sun, J.; Hei, M.; Wang, L.; Zhang, H.; Ma, X.; Wu, H.; Li, X.; Sun, H.; Zhou, W.; Shi, Y.; Wang, Y.; Gu, X.; Yang, T.; Lu, Y.; Du, L.; Chen, C.; Lee, S. K.; Zhou, W. Assessment of Neonatal Intensive Care Unit Practices, Morbidity, and Mortality Among Very Preterm Infants in China. JAMA Netw. Open. 2021, 4 (8), e2118904. DOI: 10.1001/jamanetworkopen.2021.18904
4. Bell, E. F.; Hintz, S. R.; Hansen, N. I,; Bann, C. M.; Wyckoff, M. H.; DeMauro, S. B.; Walsh, M. C,.; Vohr, B. R.; Stoll, B. J.; Carlo, W. A.; Van Meurs, K. P.; Rysavy, M.A.; Patel, R. M.; Merhar, S. L.; Sánchez, P. J.; Laptook, A. R.; Hibbs, A. M.; Cotton, C. M.; D'Angio, C. T,.; Winter, S.; Fuller, J.; Das, A. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018. JAMA 2022, 327 (3), 248-263. DOI: 10.1001/jama.2021.23580
5. Jeon, G. W.; Oh, M.; Chang, Y. S. Definitions of Bronchopulmonary Dysplasia and Long-Term Outcomes of Extremely Preterm Infants in Korean Neonatal Network. Sci. Rep. 2021, 11 (1), 24349OI: 10.1038/s41598-021-03644-7
6. Jeon, G. W. Oh, M.; Lee, J.; Jun, Y. H.; Chang, Y. S. Comparison of Definitions of Bronchopulmonary Dysplasia to Reflect the Long-Term Outcomes of Extremely Preterm Infants. Sci. Rep. 2022, 12 (1), 18095. DOI: 10.1038/s41598-022-22920-8
7. Katz, T. A.; Vliegenthart, R. J. S.; Aarnoudse-Moens, C. S. H.; Leemhuis, A. G.; Beuger, S.; Blok, G. J.; van Brakel, M. J. M.; van den Heuvel, M. E. N.; van Kempen, A. A. M. W.; Lutterman, C.; Rijpert, M.; Schiering, I. A.; Ran, N. C.; Visser, F.; Wilms, J.; van Kaam, A. H.; Onland, W. Severity of Bronchopulmonary Dysplasia and Neurodevelopmental Outcome at 2 and 5 Years Corrected Age. J. Pediatr. 2022, 243, 40-46.e2. DOI: 10.1016/j.jpeds.2021.12.018
8. Katz, T. A.; van Kaam, A. H.; Schuit, E.; Mugie, S. M.; Aarnoudse-Moens, C. S. H.; Weber, E. H.; de Groof,F.; van Laerhoven, H.; Counsilman, C. E.; van der Schoor, S. R. D.; Rijpert, M.; Schiering, I. A.; Wilms, J.; Leemhuis, A. G.; Onland, W. Comparison of New Bronchopulmonary Dysplasia Definitions on Long-Term Outcomes in Preterm Infants. J Pediatr. 2023, 253, 86-93.e4. DOI: 10.1016/j.jpeds.2022.09.022
9. Jensen, E. A.; Edwards, E. M.; Greenberg, L. T.; Soll, R. F.; Ehret, D. E. Y.; Horbar, J. D. Severity of Bronchopulmonary Dysplasia Among Very Preterm Infants in the United States. Pediatrics 2021, 148 (1), e2020030007. DOI: 10.1542/peds.2020-030007
New Study Uses MSPE with GC–MS to Analyze PFCAs in Water
January 20th 2025Scientists from the China University of Sciences combined magnetic solid-phase extraction (MSPE) with gas chromatography–mass spectrometry (GC–MS) to analyze perfluoro carboxylic acids (PFCAs) in different water environments.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.
